A working list of startups operating across Florida, with ecosystem organizations available as separate views. Search, sort, filter — submit additions anytime.
Betaliq is a collaboration between Novaliq, GMBH, and BLP Management Group, LLC. It was formed to develop ophthalmic beta-blockers using Novaliq’s patented EyeSol non-water formulation technology. The company is developing two beta-blockers, for the treatment of glaucoma. BTQ 1901 is an EyeSol based formulation of a potent selective beta-blocker that has not previously been used to treat glaucoma. BTQ 1902 is an EyeSol based formulation of timolol, the most commonly prescribed beta-blockers.
Biotechnology—2018Betaliq is a collaboration between Novaliq, GMBH, and BLP Management Group, LLC. It was formed to develop ophthalmic beta-blockers using Novaliq’s patented EyeSol non-water formulation technology. The company is developing two beta-blockers, for the treatment of glaucoma. BTQ 1901 is an EyeSol based formulation of a potent selective beta-blocker that has not previously been used to treat glaucoma. BTQ 1902 is an EyeSol based formulation of timolol, the most commonly prescribed beta-blockers.TPA→
002
Disruption Labs
Disruption Labs core strategy is a B2B business model, working in partnership with multi-national corporations and high-growth SMEs in the functional food & beverage and clinical therapeutic markets to improve or bio-enhance existing products areas, or create entirely new disruptive products. Disruption Labs performs R&D, including pharmacokinetic studies, to demonstrate product safety and improved efficacy, facilitating new product development from the lab bench top to product scale-up through market - offering a true end-to-end solution. In instance in which these strategic partnerships are not available, Disruption Labs plans to launch its own niche branded products, with R&D performed in-house to develop, scale-up and tech transfer, to bring to market scientifically validated, cutting-edge bio-enhanced product lines employing the proven, proprietary nanotechnology platform. Currently, Disruption Labs has developed a nano-liposomal CBD water soluble formulation, which utilizes its proprietary proven nanotechnology platform. The product is now sold under the brand Reset Bioscience, is currently being scientifically tested and validated for pharmacokinetic properties and manufactured under GMP-compliant conditions. Reset Biosciences has launched its first bio-enhanced, pharmaceutical grade, nano-liposomal product RESET Balance Jan 2019. More on RESET RESET Bioscience, a CBD and advanced wellness company, is the first to use pharmaceutical grade ingredients, and processes, for its pioneering CBD product. After extensive research, testing and validation the company is launching its debut product - RESET Balance, a 99.9% nano liposomal organic hemp CBD that compliments the body’s existing endocannabinoid system. The type of advanced nanotechnology used to produce this product uses liposomes as the trojan horse of drug delivery, providing approximately a 80% absorption/CBD effect at the cellular level, the highest in the industry today. With a commitment to quality, RESET Bioscience has spent $2M to double test for purity and efficacy, to introduce a product that will work as hard as you do to “reset” you to your baseline managing everyday stressors, including pain, anxiety, insomnia and more. RESET Balance is available in two flavors, neutral and peppermint, and is power packed with 300mg of organic triple tested CBD isolate, the most researched form of CBD on the market today, and importantly, with 0% THC. A unique attribute to RESET Balance is that it is white in color, due to the purity of the pharmaceutical grade lipids used. RESET has committed to self-regulate its developmental process, which means more safety and quality control measures have been taken to test and deliver a product that achieves real results, setting a new standard for CBD bioavailability through its proprietary nano liposomal delivery system.
Biotechnology—2017Disruption Labs core strategy is a B2B business model, working in partnership with multi-national corporations and high-growth SMEs in the functional food & beverage and clinical therapeutic markets to improve or bio-enhance existing products areas, or create entirely new disruptive products. Disruption Labs performs R&D, including pharmacokinetic studies, to demonstrate product safety and improved efficacy, facilitating new product development from the lab bench top to product scale-up through market - offering a true end-to-end solution. In instance in which these strategic partnerships are not available, Disruption Labs plans to launch its own niche branded products, with R&D performed in-house to develop, scale-up and tech transfer, to bring to market scientifically validated, cutting-edge bio-enhanced product lines employing the proven, proprietary nanotechnology platform. Currently, Disruption Labs has developed a nano-liposomal CBD water soluble formulation, which utilizes its proprietary proven nanotechnology platform. The product is now sold under the brand Reset Bioscience, is currently being scientifically tested and validated for pharmacokinetic properties and manufactured under GMP-compliant conditions. Reset Biosciences has launched its first bio-enhanced, pharmaceutical grade, nano-liposomal product RESET Balance Jan 2019. More on RESET RESET Bioscience, a CBD and advanced wellness company, is the first to use pharmaceutical grade ingredients, and processes, for its pioneering CBD product. After extensive research, testing and validation the company is launching its debut product - RESET Balance, a 99.9% nano liposomal organic hemp CBD that compliments the body’s existing endocannabinoid system. The type of advanced nanotechnology used to produce this product uses liposomes as the trojan horse of drug delivery, providing approximately a 80% absorption/CBD effect at the cellular level, the highest in the industry today. With a commitment to quality, RESET Bioscience has spent $2M to double test for purity and efficacy, to introduce a product that will work as hard as you do to “reset” you to your baseline managing everyday stressors, including pain, anxiety, insomnia and more. RESET Balance is available in two flavors, neutral and peppermint, and is power packed with 300mg of organic triple tested CBD isolate, the most researched form of CBD on the market today, and importantly, with 0% THC. A unique attribute to RESET Balance is that it is white in color, due to the purity of the pharmaceutical grade lipids used. RESET has committed to self-regulate its developmental process, which means more safety and quality control measures have been taken to test and deliver a product that achieves real results, setting a new standard for CBD bioavailability through its proprietary nano liposomal delivery system.TPA→
003
Inflammx Therapeutics
Inflammx Therapeutics is a biotechnology startup company. It was founded in Tampa, Florida in 2020.
Biotechnology—2020Inflammx Therapeutics is a biotechnology startup company. It was founded in Tampa, Florida in 2020.TPA→
004
Method Testing Labs
Method Testing Labs provides tools to cultivate, manufacture, and distribute hemp or cannabis products. The company's team is composed of researchers, chemists, pharmaceutical scientists, and former industry leaders in the cannabis and hemp industry. Method Testing Labs was founded in 2019 by Rob Radke and is headquartered in Tampa, Florida, United States.
Biotechnology—2019Method Testing Labs provides tools to cultivate, manufacture, and distribute hemp or cannabis products. The company's team is composed of researchers, chemists, pharmaceutical scientists, and former industry leaders in the cannabis and hemp industry. Method Testing Labs was founded in 2019 by Rob Radke and is headquartered in Tampa, Florida, United States.TPA→
005
Nula Therapeutics
Nula Therapeutics pioneering a new class of medicines to treat metabolic dysfunction, neurodegeneration, and cancer.
Biotechnology—2021Nula Therapeutics pioneering a new class of medicines to treat metabolic dysfunction, neurodegeneration, and cancer.TPA→
006
Psilera
Psilera develops therapies aimed at neurological and psychiatric disorders by leveraging neuroplastogens, compounds that promote brain plasticity without hallucinogenic effects. The company builds a proprietary library of serotonergic compounds and applies computational tools to design molecules for conditions such as alcohol use disorder and frontotemporal dementia. Its research pipeline emphasizes non-hallucinogenic derivatives of psychedelic compounds to provide safe and scalable treatment options. Psilera integrates medicinal chemistry, neuroscience, and pharmacology to create small-molecule drugs that address unmet medical needs. Through this approach, the company seeks to expand treatment possibilities for patients facing hard-to-treat neurological conditions.
Biotechnology—2019Psilera develops therapies aimed at neurological and psychiatric disorders by leveraging neuroplastogens, compounds that promote brain plasticity without hallucinogenic effects. The company builds a proprietary library of serotonergic compounds and applies computational tools to design molecules for conditions such as alcohol use disorder and frontotemporal dementia. Its research pipeline emphasizes non-hallucinogenic derivatives of psychedelic compounds to provide safe and scalable treatment options. Psilera integrates medicinal chemistry, neuroscience, and pharmacology to create small-molecule drugs that address unmet medical needs. Through this approach, the company seeks to expand treatment possibilities for patients facing hard-to-treat neurological conditions.TPA→